| Torrent name | Size |
|---|
 Ac-As/Acceptance Sampling.pdf | 426.97 KB |
| Ac-As/Active Control Trials.pdf | 303.68 KB |
| Ac-As/Adaptive Designs.pdf | 123.36 KB |
| Ac-As/Adaptive Dose-Finding Based on Efficacy-Toxicity Trade-Offs .pdf | 151.04 KB |
| Ac-As/Adjustment for Covariates.pdf | 169.44 KB |
| Ac-As/Adverse Event Reporting.pdf | 280.19 KB |
| Ac-As/Alpha Spending Function.pdf | 106.71 KB |
| Ac-As/Ames Test.pdf | 406.04 KB |
| Ac-As/Analysis of 2 K Tables .pdf | 136.8 KB |
| Ac-As/Analysis of Clustered Binary Data.pdf | 102.37 KB |
| Ac-As/Analysis of Heritability.pdf | 263.49 KB |
| Ac-As/Analysis of Repeated Measures Data with Missing Values- An Overview of Methods .pdf | 99.81 KB |
| Ac-As/Analysis of Variance.pdf | 1.63 MB |
| Ac-As/ANCOVA Approach for Premarketing Shelf Life Determination with Multiple Factors .pdf | 72.37 KB |
| Ac-As/Assay Development.pdf | 424.01 KB |
| Ac-As/Assay Validation.pdf | 420.15 KB |
| Ba-Ca to Ce-Cu/Bayesian Methods in Meta-Analysis.pdf | 98.43 KB |
| Ba-Ca to Ce-Cu/Bayesian Statistics.pdf | 337.79 KB |
| Ba-Ca to Ce-Cu/Bayesian Two-Stage Design for Phase II Clinical Trials.pdf | 150.68 KB |
| Ba-Ca to Ce-Cu/Bioassay.pdf | 145.55 KB |
| Ba-Ca to Ce-Cu/Bioavailability and Bioequivalence.pdf | 255.04 KB |
| Ba-Ca to Ce-Cu/Bioinformatics.pdf | 133.55 KB |
| Ba-Ca to Ce-Cu/Biologics.pdf | 428 KB |
| Ba-Ca to Ce-Cu/Biopharmaceutics.pdf | 1.1 MB |
| Ba-Ca to Ce-Cu/Blinding.pdf | 271.45 KB |
| Ba-Ca to Ce-Cu/Bootstrap, The.pdf | 265.04 KB |
| Ba-Ca to Ce-Cu/Bracketing Design.pdf | 60.47 KB |
| Ba-Ca to Ce-Cu/Bridging Studies.pdf | 213.63 KB |
| Ba-Ca to Ce-Cu/Calibration.pdf | 336.89 KB |
| Ba-Ca to Ce-Cu/Canadian Health Products and Food Branch (HPFB) and Therapeutic Products Directorate (TPD).pdf | 227.74 KB |
| Ba-Ca to Ce-Cu/Cancer Trials.pdf | 324.18 KB |
| Ba-Ca to Ce-Cu/Carcinogenicity Studies of Pharmaceuticals.pdf | 505.98 KB |
| Ba-Ca to Ce-Cu/Carry-Forward Analysis.pdf | 252.26 KB |
| Ba-Ca to Ce-Cu/Case-Control Studies, Inference in.pdf | 200.7 KB |
| Ba-Ca to Ce-Cu/Center Weighting in Multicenter Trials.pdf | 118.2 KB |
| Ba-Ca to Ce-Cu/Clinical Data Management.pdf | 784.86 KB |
| Ba-Ca to Ce-Cu/Clinical Endpoint.pdf | 166.4 KB |
| Ba-Ca to Ce-Cu/Clinical Pharmacology.pdf | 131.6 KB |
| Ba-Ca to Ce-Cu/Clinical Trial Process.pdf | 165.03 KB |
| Ba-Ca to Ce-Cu/Clinical Trial Simulation.pdf | 101.34 KB |
| Ba-Ca to Ce-Cu/Clinical Trial Simulations for Earlier Development Phases.pdf | 88.58 KB |
| Ba-Ca to Ce-Cu/Clinical Trial Simulations for Later Development Phases.pdf | 123.53 KB |
| Ba-Ca to Ce-Cu/Clinical Trials.pdf | 123.53 KB |
| Ba-Ca to Ce-Cu/Cluster Trials.pdf | 173.14 KB |
| Ba-Ca to Ce-Cu/Clustered Study Designs- Power Analysis.pdf | 259.29 KB |
| Ba-Ca to Ce-Cu/Combination Drug Clinical Trial.pdf | 168.96 KB |
| Ba-Ca to Ce-Cu/Comparing Variabilities in Clinical Research.pdf | 680.57 KB |
| Ba-Ca to Ce-Cu/Confidence Interval and Hypothesis Testing.pdf | 187.53 KB |
| Ba-Ca to Ce-Cu/Confounding and Interaction.pdf | 284 KB |
| Ba-Ca to Ce-Cu/Content Uniformity.pdf | 198.67 KB |
| Ba-Ca to Ce-Cu/Contract Research Organization (CRO).pdf | 204.94 KB |
| Ba-Ca to Ce-Cu/Correlated Probit Model.pdf | 115.81 KB |
| Ba-Ca to Ce-Cu/Cost-Effectiveness Analysis.pdf | 247.13 KB |
| Ba-Ca to Ce-Cu/Crossover Design.pdf | 323.43 KB |
| Ba-Ca to Ce-Cu/Cutoff Designs.pdf | 329.96 KB |
| Da-Fa to Fo-In/Data Mining and Biopharmaceutical Research.pdf | 461.43 KB |
| Da-Fa to Fo-In/Data Monitoring Committees (DMC).pdf | 425.54 KB |
| Da-Fa to Fo-In/Diagnostic Imaging.pdf | 367.55 KB |
| Da-Fa to Fo-In/Dose Proportionality.pdf | 479.72 KB |
| Da-Fa to Fo-In/Dose Response Analysis in Clinical Trials.pdf | 245.69 KB |
| Da-Fa to Fo-In/Dose Response Study Design.pdf | 327.32 KB |
| Da-Fa to Fo-In/Dropout.pdf | 250.67 KB |
| Da-Fa to Fo-In/Drug Development.pdf | 294.99 KB |
| Da-Fa to Fo-In/Ecologic Inference.pdf | 179.99 KB |
| Da-Fa to Fo-In/ED50-ED90.pdf | 676.45 KB |
| Da-Fa to Fo-In/Enrichment Design.pdf | 138.08 KB |
| Da-Fa to Fo-In/Equivalence Trials.pdf | 251.25 KB |
| Da-Fa to Fo-In/Ethnic Factors.pdf | 132.05 KB |
| Da-Fa to Fo-In/Expiration Dating Period.pdf | 304.72 KB |
| Da-Fa to Fo-In/Exploratory Factor Analysis.pdf | 602.15 KB |
| Da-Fa to Fo-In/Extra Variation Models.pdf | 925.01 KB |
| Da-Fa to Fo-In/Factor Analysis.pdf | 86.11 KB |
| Da-Fa to Fo-In/Factorial Designs.pdf | 738.42 KB |
| Da-Fa to Fo-In/Failure-Time Model.pdf | 155.42 KB |
| Da-Fa to Fo-In/False Discovery Rate (FDR).pdf | 310.41 KB |
| Da-Fa to Fo-In/Food and Drug Administration.pdf | 302.91 KB |
| Da-Fa to Fo-In/Generalizability Probability in Clinical Research.pdf | 178.69 KB |
| Da-Fa to Fo-In/Generalized Estimating Equation.pdf | 178.69 KB |
| Da-Fa to Fo-In/Generalized Estimating Equations (GEE) Method- Sample Size Estimation.pdf | 92.11 KB |
| Da-Fa to Fo-In/Genetic Linkage and Linkage Disequilibrium Analysis.pdf | 353.25 KB |
| Da-Fa to Fo-In/Global Database and System.pdf | 319.82 KB |
| Da-Fa to Fo-In/Good Clinical Practice.pdf | 276.82 KB |
| Da-Fa to Fo-In/Good Programming Practice.pdf | 275.27 KB |
| Da-Fa to Fo-In/Good Statistics Practice.pdf | 238.62 KB |
| Da-Fa to Fo-In/Group Sequential Methods.pdf | 413 KB |
| Da-Fa to Fo-In/Group Sequential Tests and Variance Heterogeneity in Clinical Trials.pdf | 106.64 KB |
| Da-Fa to Fo-In/Hypotheses and False Positive Rate in Active Control Non-Inferiority Trials.pdf | 302.42 KB |
| Da-Fa to Fo-In/Imputation in Clinical Research.pdf | 177.46 KB |
| Da-Fa to Fo-In/Imputation with Item Nonrespondents.pdf | 257.67 KB |
| Da-Fa to Fo-In/In Vitro Bioequivalence Testing.pdf | 300.06 KB |
| Da-Fa to Fo-In/In Vitro Dissolution Profile Comparison.pdf | 300.14 KB |
| Da-Fa to Fo-In/In Vitro Micronucleus Test.pdf | 606.72 KB |
| Da-Fa to Fo-In/Individual Bioequivalence.pdf | 333.13 KB |
| Da-Fa to Fo-In/Instrument Development and Validation.pdf | 435.58 KB |
| Da-Fa to Fo-In/Integrated Summary Report.pdf | 511.41 KB |
| Da-Fa to Fo-In/Intention-to-Treat Analyses (ITT).pdf | 171.76 KB |
| Da-Fa to Fo-In/Interactive Voice Randomization System (IVRS).pdf | 649.65 KB |
| Da-Fa to Fo-In/Interim Analysis.pdf | 560.78 KB |
| Da-Fa to Fo-In/International Conference on Harmonization (ICH).pdf | 161.68 KB |
| Da-Fa to Fo-In/Investigating Quality-of-Life in Clinical Trials.pdf | 464.59 KB |
| Ka-Mu/Coefficients in Medical Research.pdf | 141.79 KB |
| Ka-Mu/Kaplan-Meier Estimator.pdf | 589.78 KB |
| Ka-Mu/Kullback-Leibler Divergence for Evaluating Equivalence.pdf | 230.27 KB |
| Ka-Mu/Laboratory Analyses.pdf | 313.73 KB |
| Ka-Mu/Latent Class Analysis.pdf | 155.9 KB |
| Ka-Mu/Lilly Reference Ranges.pdf | 563.45 KB |
| Ka-Mu/Local Influence Analysis.pdf | 76.26 KB |
| Ka-Mu/Logistic Regression in Three-Point Designs.pdf | 145.87 KB |
| Ka-Mu/Logistic Regression.pdf | 876.71 KB |
| Ka-Mu/Maximum Tolerable Dose for Cancer Chemotherapy.pdf | 350.52 KB |
| Ka-Mu/McNemar's Test.pdf | 85.1 KB |
| Ka-Mu/Measuring Agreement.pdf | 454.55 KB |
| Ka-Mu/MedDRA and Its Impact on Pharmaceutical Development.pdf | 272.06 KB |
| Ka-Mu/Medical Devices.pdf | 468.14 KB |
| Ka-Mu/Meta-Analysis of Therapeutic Trials.pdf | 577.69 KB |
| Ka-Mu/Microarray Gene Expression.pdf | 1.14 MB |
| Ka-Mu/Minimization Procedure.pdf | 210.44 KB |
| Ka-Mu/Minimum Effective Dose.pdf | 210.44 KB |
| Ka-Mu/Ministry of Health, Labour and Welfare and Pharmaceutical Administration in Japan.pdf | 596.13 KB |
| Ka-Mu/Missing Values in Repeated Measurement Designs.pdf | 127.75 KB |
| Ka-Mu/Mixed Effects Models.pdf | 217.62 KB |
| Ka-Mu/Modified Large Sample Method.pdf | 333.38 KB |
| Ka-Mu/Multicenter Trials.pdf | 172.03 KB |
| Ka-Mu/Multicollinearity.pdf | 149.45 KB |
| Ka-Mu/Multinational Clinical Trial.pdf | 309.03 KB |
| No-Pr/Noninferiority Analysis in Active Controlled Clinical Trials.pdf | 174.94 KB |
| No-Pr/Odds Ratio.pdf | 293.18 KB |
| No-Pr/Onset of Action.pdf | 119.93 KB |
| No-Pr/Ordered Multiple Class Receiver Operating Characteristic (ROC) Analysis.pdf | 139.19 KB |
| No-Pr/Outlier Detection in Clinical Research.pdf | 558.61 KB |
| No-Pr/P-Values, Evidence and Multiplicity Considerations for Controlled Clinical Trials.pdf | 450.28 KB |
| No-Pr/P-Values.pdf | 537.72 KB |
| No-Pr/Parallel Design.pdf | 215.68 KB |
| No-Pr/Patient Compliance.pdf | 245.67 KB |
| No-Pr/Percentile Charts on Correlated Measures.pdf | 177.15 KB |
| No-Pr/Pharmacodynamic Issues.pdf | 348.7 KB |
| No-Pr/Pharmacodynamics with Covariates.pdf | 524.25 KB |
| No-Pr/Pharmacodynamics with No Covariates.pdf | 371.3 KB |
| No-Pr/Pharmacoeconomics.pdf | 1017.55 KB |
| No-Pr/Phase I Cancer Clinical Trials.pdf | 334.99 KB |
| No-Pr/Placebo Effect.pdf | 216.1 KB |
| No-Pr/Population Bioequivalence.pdf | 304.18 KB |
| No-Pr/Population PK-PD Analysis.pdf | 245.11 KB |
| No-Pr/Postmarketing Adverse Drug Event Signaling.pdf | 618.88 KB |
| No-Pr/Postmarketing Surveillance.pdf | 328.58 KB |
| No-Pr/Power.pdf | 103.8 KB |
| No-Pr/Prediction Trees.pdf | 184.54 KB |
| No-Pr/Principal Component Analysis.pdf | 125.3 KB |
| No-Pr/Process Validation.pdf | 987.39 KB |
| No-Pr/Profile Analysis.pdf | 212.46 KB |
| No-Pr/Proportion of Treatment Effect.pdf | 87.1 KB |
| No-Pr/Proportional Hazards Regression Model.pdf | 343.71 KB |
| No-Pr/Protocol Development.pdf | 168.99 KB |
| Qt-St to Su-Zs/QT Analysis.pdf | 170.37 KB |
| Qt-St to Su-Zs/Randomization.pdf | 221.71 KB |
| Qt-St to Su-Zs/Rank Regression in Stability Analysis.pdf | 218.93 KB |
| Qt-St to Su-Zs/Release Targets.pdf | 267.56 KB |
| Qt-St to Su-Zs/Reliability.pdf | 293.19 KB |
| Qt-St to Su-Zs/Reproducibility Probability in Clinical Research.pdf | 474.64 KB |
| Qt-St to Su-Zs/Reproductive-Developmental Studies.pdf | 342.16 KB |
| Qt-St to Su-Zs/Response Surface Methodology.pdf | 976.75 KB |
| Qt-St to Su-Zs/Risk Ratio Analysis.pdf | 91.58 KB |
| Qt-St to Su-Zs/Robust Analysis for Crossover Design.pdf | 583.02 KB |
| Qt-St to Su-Zs/ROC Curve.pdf | 654.31 KB |
| Qt-St to Su-Zs/Sample Size Calculation Based on Nonparametric Statistics.pdf | 372.4 KB |
| Qt-St to Su-Zs/Sample Size Calculation for Survival Data.pdf | 301.56 KB |
| Qt-St to Su-Zs/Sample Size Determination.pdf | 657.55 KB |
| Qt-St to Su-Zs/Sample Size Re-estimation Based on Observed Treatment Difference.pdf | 213.11 KB |
| Qt-St to Su-Zs/Screening Design.pdf | 59.86 KB |
| Qt-St to Su-Zs/Selection of Control in Clinical Trials.pdf | 243.43 KB |
| Qt-St to Su-Zs/Sequential Estimation for the Additive Hazards Rate Model with Staggered Entry.pdf | 87.02 KB |
| Qt-St to Su-Zs/Slope Approach for Assessment of Dose Proportionality-Linearity Under a Crossover Design.pdf | 643.36 KB |
| Qt-St to Su-Zs/Spatio-Temporal Modeling.pdf | 553.61 KB |
| Qt-St to Su-Zs/Specifications.pdf | 96.98 KB |
| Qt-St to Su-Zs/SROC Curve.pdf | 192.28 KB |
| Qt-St to Su-Zs/Stability Analysis for Frozen Drug Products.pdf | 217.59 KB |
| Qt-St to Su-Zs/Stability Matrix Designs.pdf | 242.36 KB |
| Qt-St to Su-Zs/Statistical Principles for Clinical Trials.pdf | 202.97 KB |
| Qt-St to Su-Zs/Statistical Process Control.pdf | 799.2 KB |
| Qt-St to Su-Zs/Statistical Significance.pdf | 222.41 KB |
| Qt-St to Su-Zs/Statistical Tests for Biomarker Development with Applications to Genetics Data.pdf | 119.04 KB |
| Qt-St to Su-Zs/Structural Equation Model.pdf | 137.69 KB |
| Qt-St to Su-Zs/Stuart-Maxwell Test.pdf | 80.47 KB |
| Qt-St to Su-Zs/Subgroup Analysis.pdf | 360.36 KB |
| Qt-St to Su-Zs/Subject-Treatment Interaction.pdf | 214.36 KB |
| Qt-St to Su-Zs/Survival Analysis.pdf | 546.89 KB |
| Qt-St to Su-Zs/Testing for Qualitative Interaction.pdf | 111 KB |
| Qt-St to Su-Zs/Therapeutic Equivalence.pdf | 252.46 KB |
| Qt-St to Su-Zs/Titration Design.pdf | 210.33 KB |
| Qt-St to Su-Zs/Toxicological Studies.pdf | 578.03 KB |
| Qt-St to Su-Zs/Trend Estimation.pdf | 97.49 KB |
| Qt-St to Su-Zs/Two-Stage Design- Phase II Cancer Clinical Trials.pdf | 163.88 KB |
| Qt-St to Su-Zs/USP Tests.pdf | 90.62 KB |
| Qt-St to Su-Zs/Vaccine Clinical Trials.pdf | 709.97 KB |
| Qt-St to Su-Zs/Validation of Quantitative and Qualitative Assays.pdf | 988.58 KB |
| Qt-St to Su-Zs/Validity of LOCF.pdf | 298.81 KB |
| Qt-St to Su-Zs/Z-Score.pdf | 69 KB |
